RVMD · NASDAQ · STOCK
Revolution Medicines, Inc.
$205.54
52W $34.21 – $208.76
61/100
$43.70B
-23.2
1.40
Is RVMD Bullish or Bearish?
Bullish.
Innellis AI committee rates Revolution Medicines, Inc. (RVMD) Buy with a composite score of 61/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.96 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.04 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 9.4x prices in significant intangible value — Value
- ROE of only -54.1% -- cheap may mean cheap for a reason — Value
- RSI at 71 is in overbought territory — Technical
- Weekly RSI at 85 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 18.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
61/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 39%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 9.4x prices in significant intangible value
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 71 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock
− Bollinger bandwidth of 18.2% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 12 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
70.9
Overbought
MACD Histogram
1.398
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.96
Inside Bands
Price vs Moving Averages
EMA 9
$198.18
Above
EMA 21
$191.46
Above
EMA 50
$178.50
Above
EMA 200
$129.30
Above
Fundamental Analysis
Valuation
67
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-23.2×
P/B Ratio
16.63×
PEG Ratio
0.41
Dividend Yield
0.00%
52W High
$208.76
52W Low
$34.21
Quality & Growth
ROE
-6935.0%
ROA
-4804.8%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.25
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -23.2 (inexpensive relative to a 15-40x range); Price-to-book of 16.6x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -69.3%; Return on assets of -48.0%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 11.38 (healthy short-term liquidity); Debt-to-equity of 0.25; Free cash flow per share is negative (-7.53); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full RVMD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →